Protagonist Therapeutics (PTGX) FCF Margin (2017 - 2026)
Protagonist Therapeutics (PTGX) reported FCF Margin of 87.02% for Q1 2026, down 52775.0% on a YoY basis from N/an in Q1 2025, and up 83.21% sequentially from 518.45% in Q4 2025.
Protagonist Therapeutics (PTGX) FCF Margin (2017 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 10 years of FCF Margin data on file, last reported at 87.02% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 52775.0% year-over-year to 87.02%; the trailing twelve-month figure through Mar 2026 stood at 159.04% (down 32489.0% YoY), and the FY2025 full-year result was 121.87%, up 7980.0% from the prior year.
- FCF Margin rose to 87.02% in Q1 2026, from 518.45% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 6445.62% in Q2 2024 to a low of 1621.07% in Q2 2022.
- A 5-year average of 279.58% and a median of 63.06% in 2025 frame the typical range for FCF Margin.
- Peak annual rise in FCF Margin reached 57338 bps in 2025, while the deepest fall reached 695658 bps in 2025.
- Tracing PTGX's FCF Margin over 5 years: stood at 1621.07% in 2022, then soared by 102 bps to 33.88% in 2023, then tumbled by 153 bps to 17.87% in 2024, then slumped by 2801 bps to 518.45% in 2025, then soared by 83 bps to 87.02% in 2026.
- Business Quant data shows PTGX's FCF Margin at 87.02% in Q1 2026, 518.45% in Q4 2025, and 39.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | -87.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87.02% |
| Dec 31, 2025 | -518.45% |
| Sep 30, 2025 | -39.09% |
| Jun 30, 2025 | -510.96% |
| Mar 31, 2025 | 440.73% |
| Dec 31, 2024 | -17.87% |
| Sep 30, 2024 | -612.47% |
| Jun 30, 2024 | 6,445.62% |
| Mar 31, 2024 | -10.85% |
| Dec 31, 2023 | 33.88% |
| Jun 30, 2022 | -1,621.07% |
| Mar 31, 2022 | -147.50% |
| Dec 31, 2021 | -314.01% |
| Sep 30, 2021 | -270.80% |
| Jun 30, 2021 | -1,070.33% |
| Mar 31, 2021 | -466.20% |
| Dec 31, 2020 | -336.14% |
| Sep 30, 2020 | -124.77% |
| Jun 30, 2020 | -347.68% |
| Mar 31, 2020 | -438.33% |